EUVIMEDEUVIMED entdecken
Crossref

Immunogenicity-masking delivery of uricase against hyperuricemia and gout

Zhenglan Ban, Madi Sun, Huihong Ji, Quanxin Ning, Chuanxu Cheng, Tongfei Shi, Minghao He, Xuenian Chen, Huanfen Lu, Xuan He, Chenyang Guo, Yan He und 2 weitere

Journal of Controlled Release · 2024-08 · 372 · 862-873

DOI: 10.1016/j.jconrel.2024.06.042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-08. Verfasst von Zhenglan Ban und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, South China University of Technology, Guangzhou, Guangdong 510006, PR China; National Engineering Research Center for Tissue Rest…. Hauptthemen laut MEDLINE: Urate Oxidase, Hyperuricemia, Gout, Erythrocytes. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Improving the activity of uricase and lowering its immunogenicity remain significant challenges in the enzyme replacement management of hyperuricemia and related inflammatory diseases. Herein, an immunogenicity-masking strategy based on engineered red blood cells (RBCs) was developed for effective uricase delivery against both hyperuricemia and gout. The dynamic membrane of RBCs enabled high resistance to protease inactivation and hydrogen peroxide accumulation. Benefiting from these advantages, a single infusion of RBC-loaded uricase (Uri@RBC) performed prolonged blood circulation and sustained hyperuricemia management. Importantly, RBCs masked the immunogenicity of uricase, leading to the maintenance of UA-lowering performance after repeated infusion through reduced antibody-mediated macrophage clearance. In an acute gout model, Uri@RBC profoundly alleviated joint edema and inflammation with minimal systemic toxicity. This study supports the employment of immunogenicity-masking tools for efficient and safe enzyme delivery, and this strategy may be leveraged to improve the usefulness of enzyme replacement therapies for managing a wide range of inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urate OxidaseHyperuricemiaGoutErythrocytesAnimalsMaleHumansUric AcidMiceMice, Inbred C57BL

Stichwörter der Autor:innen

GoutHyperuricemiaImmunogenicityRed blood cellUricase

Substanzen

Urate OxidaseUric Acid

Autor:innen und Institutionen

  • School of Medicine, South China University of Technology, Guangzhou, Guangdong 510006, PR China; National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guan…
  • National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, Guangdong 510006, PR China; School of Biomedical Sciences and Engineering, South China Uni…
  • Department of Rheumatology and Immunology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510630, PR China.
  • Department of Rheumatology and Immunology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510630, PR China. Electronic address: heyi1983@smu.edu.cn.

Zitieren

APA

Ban, Z., Sun, M., Ji, H., Ning, Q., Cheng, C., Shi, T., He, M., Chen, X., Lu, H., He, X., Guo, C., He, Y., Shao, D., & He, Y. (2024). Immunogenicity-masking delivery of uricase against hyperuricemia and gout. Journal of Controlled Release, 372, 862-873. https://doi.org/10.1016/j.jconrel.2024.06.042

Vancouver

Ban Z, Sun M, Ji H, Ning Q, Cheng C, Shi T, et al. Immunogenicity-masking delivery of uricase against hyperuricemia and gout. Journal of Controlled Release. 2024;372:862-873. doi:10.1016/j.jconrel.2024.06.042

BibTeX
@article{Ban2024,
  author = {Ban, Zhenglan and Sun, Madi and Ji, Huihong and Ning, Quanxin and Cheng, Chuanxu and Shi, Tongfei and He, Minghao and Chen, Xuenian and Lu, Huanfen and He, Xuan and Guo, Chenyang and He, Yan and Shao, Dan and He, Yi},
  title = {Immunogenicity-masking delivery of uricase against hyperuricemia and gout},
  journal = {Journal of Controlled Release},
  year = {2024},
  volume = {372},
  pages = {862--873},
  doi = {10.1016/j.jconrel.2024.06.042}
}
Kostenlos starten →